tradingkey.logo
tradingkey.logo
Search

Edesa Biotech Inc

EDSA
Add to Watchlist
5.110USD
-0.140-2.67%
Close 07-31 16:00ETQuotes delayed by 15 min
45.41MMarket Cap
LossP/E TTM

More Details of Edesa Biotech Inc Company

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.

Edesa Biotech Inc Info

Ticker SymbolEDSA
Company nameEdesa Biotech Inc
IPO dateAug 25, 2008
CEONijhawan (Pardeep)
Number of employees16
Security typeOrdinary Share
Fiscal year-endAug 25
Address100 Spy Crt
CityMARKHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeL3R 5H6
Phone19054751234
Websitehttps://www.edesabiotech.com/
Ticker SymbolEDSA
IPO dateAug 25, 2008
CEONijhawan (Pardeep)

Company Executives of Edesa Biotech Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Pardeep (Par) Nijhawan, M.D.
Dr. Pardeep (Par) Nijhawan, M.D.
Chief Executive Officer, Corporate Secretary, Director
Chief Executive Officer, Corporate Secretary, Director
823.00K
+0.41%
Mr. Patrick Marshall
Mr. Patrick Marshall
Independent Director
Independent Director
72.13K
+26.34%
Mr. Carlo Sistilli
Mr. Carlo Sistilli
Independent Chairman of the Board
Independent Chairman of the Board
49.94K
+38.05%
Ms. Joan Chypyha
Ms. Joan Chypyha
Independent Director
Independent Director
30.03K
+63.27%
Dr. Charles V. Olson
Dr. Charles V. Olson
Independent Director
Independent Director
30.00K
+63.33%
Mr. Sean Arthur Macdonald
Mr. Sean Arthur Macdonald
Independent Director
Independent Director
--
--
Dr. Michael J. Brooks, Ph.D.
Dr. Michael J. Brooks, Ph.D.
President
President
--
--
Mr. David Liu
Mr. David Liu
Independent Director
Independent Director
--
--
Mr. Peter J. Weiler
Mr. Peter J. Weiler
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Pardeep (Par) Nijhawan, M.D.
Dr. Pardeep (Par) Nijhawan, M.D.
Chief Executive Officer, Corporate Secretary, Director
Chief Executive Officer, Corporate Secretary, Director
823.00K
+0.41%
Mr. Patrick Marshall
Mr. Patrick Marshall
Independent Director
Independent Director
72.13K
+26.34%
Mr. Carlo Sistilli
Mr. Carlo Sistilli
Independent Chairman of the Board
Independent Chairman of the Board
49.94K
+38.05%
Ms. Joan Chypyha
Ms. Joan Chypyha
Independent Director
Independent Director
30.03K
+63.27%
Dr. Charles V. Olson
Dr. Charles V. Olson
Independent Director
Independent Director
30.00K
+63.33%
Mr. Sean Arthur Macdonald
Mr. Sean Arthur Macdonald
Independent Director
Independent Director
--
--

FAQs

Who are the top five shareholders of Edesa Biotech Inc?

The top five shareholders of Edesa Biotech Inc are: Dr. Pardeep (Par) Nijhawan, M.D.

How many institutions hold shares of Edesa Biotech Inc (EDSA)?

As of 2026Q1, 47 institutions hold shares of Edesa Biotech Inc, with a combined market value of approximately 4.36M, accounting for 49.07% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1326453.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.